Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) Target Price at $44.00

Assembly Biosciences, Inc. (NASDAQ:ASMB) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $44.00.

Several equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Guggenheim reaffirmed a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, May 4th. Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th.

Hedge Funds Weigh In On Assembly Biosciences

Several institutional investors have recently bought and sold shares of the business. Informed Momentum Co LLC raised its stake in shares of Assembly Biosciences by 1.6% in the fourth quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock worth $1,004,000 after acquiring an additional 451 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Assembly Biosciences by 4.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 800 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Assembly Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after purchasing an additional 1,212 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Assembly Biosciences by 4.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock valued at $1,095,000 after purchasing an additional 1,634 shares in the last quarter. Finally, Palumbo Wealth Management LLC increased its holdings in shares of Assembly Biosciences by 7.2% in the fourth quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock valued at $1,269,000 after purchasing an additional 2,507 shares in the last quarter. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Price Performance

Assembly Biosciences stock opened at $25.22 on Tuesday. The business has a 50 day simple moving average of $26.04 and a 200 day simple moving average of $27.72. The company has a market capitalization of $400.75 million, a PE ratio of -229.25 and a beta of 1.08. Assembly Biosciences has a one year low of $16.90 and a one year high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The company had revenue of $8.21 million for the quarter, compared to the consensus estimate of $9.27 million. Equities analysts anticipate that Assembly Biosciences will post 1.9 earnings per share for the current fiscal year.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.